Skip to main content
Log in

Atrial Fibrillation: A Risk Factor for Increased Mortality – An AVID Registry Analysis

Journal of Interventional Cardiac Electrophysiology Aims and scope Submit manuscript

Abstract

Emerging evidence suggests that atrial fibrillation is not a benign arrhythmia. It is associated with increased risk of death. The magnitude of association is controversial and potential causes remain unknown. Patients in the registry of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial form the basis for this report. Baseline variables, in particular the presence or absence of a history of atrial fibrillation/flutter, were examined in relation to survival. Multivariate Cox regression was used to adjust for differences in important baseline co-variables using 27 pre-selected variables. There were 3762 subjects who were followed for an average of 773±420 days; 1459 (39%) qualified with ventricular fibrillation and 2303 (61%) with ventricular tachycardia. A history of atrial fibrillation/flutter was present in 24.4 percent. There were many differences in baseline variables between those with and those without a history of atrial fibrillation/flutter. After adjustment for baseline differences, a history of atrial fibrillation/flutter remained a significant independent predictor of mortality, (relative risk=1.20; 95% confidence intervals=1.03−1.40; p=0.020). Antiarrhythmic drug use, other than amiodarone or sotalol, was also a significant independent predictor of mortality (relative risk 1.34; 95% confidence intervals 1.07−1.69, p=0.011. Atrial fibrillation/flutter is a significant independent risk factor for increased mortality in patients presenting with ventricular tachyarrhythmias. This risk may have been overestimated in previous studies that could not adjust for the proarrhythmic effects of antiarrhythmic drugs other than amiodarone or sotalol.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Carson PE, Johnson CR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-Heft VA Cooperative Studies Group. Circulation 1993;87:2 (Suppl 6) VI-102-10.

    Google Scholar 

  2. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-952.

    Google Scholar 

  3. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;32:695-703.

    Google Scholar 

  4. Bourassa MG, Gurne O, Bangdiwala SI, et al. Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J Am Coll Cardiol 1993;22:(Suppl A):14A-19A.

    Google Scholar 

  5. The AVID investigators. Antiarrhythmics Versus Implantable Defibrillators (AVID)-Rationale, design and methods. Am J Cardiol 1995;75:470-475.

    Google Scholar 

  6. Anderson JL, Hallstrom AP, Epstein AE, et al. Design and results of the Antiarrhythmics Vs Implantable Defibrillators (AVID) Registry. Circulation 1999;99:1692-1699.

    Google Scholar 

  7. Kaplan EL, Maier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.

    Google Scholar 

  8. Cox DR. Regression models and life tables. J Roy Stat Soc 1972;34:187-202.

    Google Scholar 

  9. Kannel WB, Wolf PA, Benjamin EF, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N.

    Google Scholar 

  10. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor of stroke: the Framingham Study. Stroke 1991;22:983-988.

    Google Scholar 

  11. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760-1764.

    Google Scholar 

  12. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG, for the SPAF Investigators. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-532.

    Google Scholar 

  13. Stevenson WG, Stevenson LW, Middlekauff HR, et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996;28:1458-1463.

    Google Scholar 

  14. Crijns HJ, Tjeerdsma G, de Kam PJ, Boomsma F, van Gelder IC, van den Berg MP, van Veldhuisen DJ. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 2000;21:1238-1245.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wyse, D.G., Love, J.C., Yao, Q. et al. Atrial Fibrillation: A Risk Factor for Increased Mortality – An AVID Registry Analysis. J Interv Card Electrophysiol 5, 267–273 (2001). https://doi.org/10.1023/A:1011460631369

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011460631369

Navigation